DIAGNOS Inc. (DGNOF)
OTCMKTS · Delayed Price · Currency is USD
0.1900
+0.0067 (3.66%)
Aug 22, 2025, 4:00 PM EDT
DIAGNOS Revenue
DIAGNOS had revenue of 19.40K CAD in the quarter ending June 30, 2025, a decrease of -47.12%. This brings the company's revenue in the last twelve months to 86.51K, down -47.10% year-over-year. In the fiscal year ending March 31, 2025, DIAGNOS had annual revenue of 103.80K, down -39.00%.
Revenue (ttm)
86.51K CAD
Revenue Growth
-47.10%
P/S Ratio
301.82
Revenue / Employee
3.93K CAD
Employees
22
Market Cap
19.14M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 103.80K | -66.36K | -39.00% |
Mar 31, 2024 | 170.16K | -315.59K | -64.97% |
Mar 31, 2023 | 485.75K | 46.92K | 10.69% |
Mar 31, 2022 | 438.83K | 171.76K | 64.31% |
Mar 31, 2021 | 267.07K | -64.44K | -19.44% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
DIAGNOS News
- 8 days ago - DIAGNOS to Extend Stock Warrants Exercise Period - GlobeNewsWire
- 10 days ago - DIAGNOS Announces Extension of Stock Warrants Exercise Period - GlobeNewsWire
- 2 months ago - DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States - GlobeNewsWire
- 2 months ago - DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market - GlobeNewsWire
- 3 months ago - DIAGNOS Announces the Engagement of Allele Capital Partners - GlobeNewsWire
- 3 months ago - DIAGNOS Announces Amendment to Convertible Debentures - GlobeNewsWire
- 4 months ago - DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application - GlobeNewsWire
- 4 months ago - DIAGNOS Provides Additional Information on Amendment to Convertible Debentures - GlobeNewsWire